Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

This trial is comparing a new treatment combination called VHAG (venetoclax, homoharringtonine, cytarabine, and G-CSF) against standard chemotherapy regimens for a rare and aggressive type of leukemia called ETP-ALL (Early T-cell Precursor Acute Lymphoblastic Leukemia). ETP-ALL is often resistant to standard treatment, and this trial tests if this new combination works better. **You may be eligible if...** - You are 14–74 years old - You have been newly diagnosed with ETP-ALL - Your overall health allows you to participate (ECOG 0–2) - Your estimated survival is at least 3 months - You are able to take venetoclax (an oral medication) - You are willing to use effective contraception during and after treatment **You may NOT be eligible if...** - You have had previous treatment for this leukemia - You cannot swallow or absorb oral medications - You have serious heart, lung, liver, or kidney problems - You have another active cancer (other than early-stage thyroid or skin cancer) - You have an uncontrolled active infection Talk to your doctor to see if this trial is right for you.